rxstat › Shortages › Cefuroxime
Cefuroxime shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Cefuroxime products are in shortage in Canada (3 of 13 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
In shortage since
Mar 31, 2020
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.
Reports by product
Active shortageCEFUROXIME FOR INJECTION, USP
750MG · POWDER FOR SOLUTION · STERIMAX INC
DIN 02422298 · since ?, no end estimate · Other (Please describe in comments)
Active shortageCEFUROXIME FOR INJECTION, USP
7.5G · POWDER FOR SOLUTION · STERIMAX INC
DIN 02422328 · since Jul 31, 2020, no end estimate · Other (Please describe in comments)
Active shortageCEFUROXIME FOR INJECTION, USP
1.5G · POWDER FOR SOLUTION · STERIMAX INC
DIN 02422301 · since Mar 31, 2020, no end estimate · Other (Please describe in comments)
ResolvedCEFTIN
125MG · GRANULES FOR SUSPENSION · SANDOZ CANADA INCORPORATED
DIN 02212307 · ended May 25, 2026 · Disruption of the manufacture of the drug.
ResolvedCEFTIN
125MG · GRANULES FOR SUSPENSION · SANDOZ CANADA INCORPORATED
DIN 02212307 · ended Apr 27, 2026 · Disruption of the manufacture of the drug.
ResolvedCEFTIN
125MG · GRANULES FOR SUSPENSION · SANDOZ CANADA INCORPORATED
DIN 02212307 · ended Nov 28, 2025 · Demand increase for the drug.
ResolvedCEFUROXIME FOR INJECTION, USP
1.5G · POWDER FOR SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02241639 · ended Jul 10, 2025 · Delay in shipping of the drug.
ResolvedCEFTIN
125MG · GRANULES FOR SUSPENSION · SANDOZ CANADA INCORPORATED
DIN 02212307 · ended Oct 2, 2023 · Demand increase for the drug.
ResolvedCEFTIN
125MG · GRANULES FOR SUSPENSION · SANDOZ CANADA INCORPORATED
DIN 02212307 · ended Oct 2, 2023 · Demand increase for the drug.
ResolvedAURO-CEFUROXIME
250MG · TABLET · AURO PHARMA INC
DIN 02344823 · ended Jan 12, 2024 · Demand increase for the drug.
ResolvedAPO-CEFUROXIME
250MG · TABLET · APOTEX INC
DIN 02244393 · ended Feb 8, 2023 · Disruption of the manufacture of the drug.
ResolvedCEFTIN
125MG · GRANULES FOR SUSPENSION · GLAXOSMITHKLINE INC
DIN 02212307 · ended Oct 28, 2022 · Demand increase for the drug.
Showing 12 of 29 reports. All reports are on file with Health Canada.
What's happening
Cefuroxime is currently affected by 3 active shortage reports filed with Health Canada by STERIMAX INC.
The reported cause is: other (please describe in comments). Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Cefuroxime is classified under “OTHER BETA-LACTAM ANTIBACTERIALS” (ATC J01DC).
Recent changes
Common questions
When will Cefuroxime be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Cefuroxime in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
All other beta-lactam antibacterials shortage statuses →
Guides: what to do when your medication is in shortage · how to read shortage reports
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.